Methanthelinium bromide

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Vagrant

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Oral anticholinergic (quaternary ammonium derivative) for the treatment of hyperhidrosis.

Pharmacodynamics (Effect)This section has been translated automatically.

Methanthelinium bromide is a quaternary ammonium derivative with anticholinergic activity and differs from atropine in the predominance of blockade of ganglionic versus peripheral muscarinergic transmission. Methanthelinium bromide reduces the tone of smooth muscles in the gastrointestinal and urogenital tract. It inhibits bronchial, salivary and sweat secretion as well as gastric acid secretion and paralyses accommodation. The duration of action of methanthelinium bromide after oral administration is clinically longer than that of atropine; it is about 6 hours at a therapeutic dose of 50-100 mg.

IndicationThis section has been translated automatically.

Situated in a stress situation with expected hyperhidrosis. Otherwise also in cases of ventriculitis, duodenal ulcer, gastritis, irritable stomach (in case of hyperacidity). Increased movement processes in the gastrointestinal tract, irritable bowel syndrome.

Pregnancy/nursing periodThis section has been translated automatically.

Lactation: contraindicated. Pregnancy: strict indication in the 3rd trimester and during delivery.

Complication(s)This section has been translated automatically.

Even when used as intended, visual performance, reactivity in road traffic or the operation of machinery may be impaired.

Dosage and method of useThis section has been translated automatically.

3 times/day 1 tbl. p.o. unchewed 30 minutes before meals with liquid.

Undesirable effectsThis section has been translated automatically.

Anticholinergic effects (e.g. dry mouth, redness of the skin, accommodation disorders, tachycardia, micturition disorders), allergic reactions.

InteractionsThis section has been translated automatically.

The anticholinergic effect of antihistamines and disopyramide may be enhanced. Tachycardia caused by β sympathomimetics may be enhanced. The absorption of simultaneously administered drugs can be delayed.

ContraindicationThis section has been translated automatically.

Urinary retention (e.g. in case of prostate adenoma), myastenia gravis.

PreparationsThis section has been translated automatically.

Vagrant

Note(s)This section has been translated automatically.

The preparation has been on the market with the indication of hyperhidrosis since 1951. A good evidence was only confirmed in recent studies (see file Dermatol 37. Blickpunkt Medizin p. 234, special publication). It has been reimbursed for primary axillary hyperhidrosis since April 2016.

PatientinformationThis section has been translated automatically.

According to the manufacturer, significant reduction of the welding rate by up to 50%, onset of effect within 30-60 minutes, well applicable before presentations, tests. Can also be used permanently for long-term treatment. Reimbursable.

LiteratureThis section has been translated automatically.

  1. Fuchslocher M et al (2002) Oral anticholinergic therapy of focal hyperhidrosis with methanthelinium bromide (vagantine). dermatologist 53: 151-152
  2. Hund M et al (2004) Randomized, placebo-controlled clinical double-blind study on the efficacy and tolerability of oral therapy with methanthelinium bromide (vagantin) in focal hyperhidrosis. JDDG 2: 343-349
  3. German Dermatological Society (DDG) (2012) S1 guideline. Definition and therapy of primary hyperhidrosis. Status 15.01. 2012

Authors

Last updated on: 29.10.2020